For murine model of Diet-induced Type 2 Diabetes, male C57BL/6J mice are used. The standard study design includes 7 days of acclimatization period, 20 weeks of diet-induced weight gain period, 5 days for diabetes verification, 14 days of treatment period, and 7 days of post-treatment observation. Study design includes 4 groups of mice (control NFD mice, DIO mice vehicle treated, DIO mice treated with reference compound, and compound treated DIO mice group), 10 mice per group.
Typical growth curves of male C57BL/6J mice maintained with high-fat (HFD) and normal fat (NFD) diet. Values are expressed as means ± SEM of 10 mice per group. *p < 0.05 compared to Vehicle group.
Diabetes treatment procedures include invasive (by IV, IP, SC, and PO routes), and noninvasive (with food) methods of drug administration. Diabetes severity is monitored using standard tests: fasting glucose, OGTT, ITT. Signs of associated pathology (cardiovascular, renal failure) observation is available at demand.
Glucose levels during oral glucose tolerance test (2 g/kg) in C57BL/6J male mice after 8 weeks of HFD. Values are expressed as means ± SEM of 10 mice per group. *p < 0.05 compared to Vehicle group.
Deliverable: A detailed study report including description of study design, experimental data and interpretation.
Sample Submission: Dry compound or compound in pre-made dosing formulation (amount required depends on the dosing levels and schedules). For example, to treat a group of 10 mice at 10 mg/kg, twice daily (b.i.d.) for 1 week, about 20 mg of the test compound is required.